Alchemia
Alchemia Limited is a former ASX-listed Australian biopharmaceutical company (delisted) that held an FDA approved drug and a late-stage oncology pipeline, operating with a small team of 11–50 employees from Eight Mile Plains, Australia.
- Company typePrivate
- Founded1995
- HeadquartersEight Mile Plains, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alchemia does
Alchemia Limited is an Australian biopharmaceutical company that was listed on the Australian Securities Exchange under the ticker ACL (status: delisted) and was headquartered in Eight Mile Plains, Australia. Founded in 1995, the company operated with a small headcount of 11–50 employees and focused on the development and commercialization of therapeutic products, including an FDA approved drug and a late-stage oncology product in its pipeline. Its leadership included Charles Walker as Chief Executive Officer and Nicolas Rey as Founder, with the company having raised approximately A$10.46 million in a March 2013 funding round led by BioScience Managers Limited.
The firm's commercial proposition centered on regulated pharmaceutical assets, with FDA approval serving as the principal value driver and the oncology pipeline representing optionality for future revenue. In 2013 it raised A$10.46 million from BioScience Managers Limited, indicating reliance on specialized life-sciences capital to advance its clinical and commercial objectives. The company subsequently delisted from the ASX, and its current operational status is unclear; its primary web address (alchemia.com.au) currently displays a parked or for-sale landing page rather than active corporate content, and the legal disclosures on that domain are attributable to Above.com Pty Ltd rather than to Alchemia itself. Given the absence of active commercial signals and the delisted equity status, available evidence does not support an inference of ongoing revenue-generating operations at scale.
Alchemia firmographics
Firmographics- Name
- Alchemia
- Website
- https://alchemia.com.au
- Company type
- Private
- Founded year
- 1995
- Operating status
- Unknown
- Headcount range
- 11–50 employees
- Short description
- Alchemia Limited is a former ASX-listed Australian biopharmaceutical company (delisted) that held an FDA approved drug and a late-stage oncology pipeline, operating with a small team of 11–50 employees from Eight Mile Plains, Australia.
- Ownership category
- akta.pro rank
Alchemia industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro industry
- Oncology & Hematology PharmaceuticalsOncology Biosimilars
Keywords
Where Alchemia is headquartered
LocationHeadquarters
- HQ city
- Eight Mile Plains
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Alchemia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Distribution channels1 record
Marketing channels2 records
Alchemia product offering
Product offeringCore offering
Alchemia is an Australian biopharmaceutical company that develops, manufactures, and commercializes FDA-approved oncology drugs. Its product portfolio includes a clinically approved cancer therapeutic and a late-stage oncology product targeting cancer treatment markets. The company sells its pharmaceutical products to healthcare providers and clinical channels.
Product overview
The domain alchemia.com.au is a parked/for-sale domain. No specific product portfolio, technology offerings, or service descriptions for a company named Alchemia are present in the source data.
Differentiator
Problem solved
Functional benefit
Products and services
- FDA-approved oncology drug An FDA-approved oncology therapeutic developed and commercialized by Alchemia for the treatment of cancer patients, sold to hospitals, oncology clinics, and healthcare providers.
- Late-stage oncology product A late-stage oncology product in Alchemia's development pipeline intended for cancer treatment applications, targeting the same healthcare provider and clinical buyer channels.
Companies that use Alchemia
Customer profileSegments1 record
Ideal customer profiles1 record
Alchemia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Alchemia partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
Alchemia competitors and assessment
Company assessmentBroad incumbents
- Telix Pharmaceuticals: ASX-listed Australian radiopharmaceutical company with commercial-stage oncology products; comparable as a larger Australian oncology player with FDA-cleared products.
- Mayne Pharma: Larger Australian specialty pharmaceutical manufacturer with branded and generic franchises; comparable as an Australian pharma operating commercially at greater breadth than Alchemia.
Direct peers
- Clinuvel Pharmaceuticals: ASX-listed Australian specialty pharmaceutical company with an FDA-approved drug and ongoing pipeline; closely comparable as an Australian innovator-drug developer with regulatory clearance.
- Bionomics: ASX-listed Australian clinical-stage biopharmaceutical company developing oncology and CNS therapeutics; comparable profile as a small-cap ASX biotech with late-stage clinical assets.
- Sirtex Medical: Australian oncology-focused company with an FDA-approved liver-cancer therapy; closely comparable given FDA-approved oncology product and Australian origin.
- Starpharma: ASX-listed Australian biotech developing dendrimer-based pharmaceutical products including oncology applications; comparable as an ASX small-cap with proprietary drug-delivery/oncology assets.
- Kazia Therapeutics: Australian oncology drug-development company with late-stage brain-cancer pipeline; closely comparable as a small-cap ASX oncology biotech.
- Imugene: ASX-listed Australian immuno-oncology company developing late-stage oncology product candidates; directly comparable as a small-cap Australian oncology biotech.
- Mesoblast: ASX-listed Australian cell-therapy/biologics company developing late-stage oncology and inflammatory disease products; directly comparable as a small-cap ASX biotech with biologics-platform assets.
- Pharmaxis: Australian specialty pharmaceutical company focused on respiratory and inflammation; comparable as an ASX-listed small-cap pharma developing and commercializing proprietary therapeutics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Alchemia social profiles
Digital presenceAlchemia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alchemia leadership team
Management profileNumber of profiles
Profiles2 records
Alchemia funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alchemia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alchemia
What does Alchemia do?
Alchemia is an Australian biopharmaceutical company that develops, manufactures, and commercializes FDA-approved oncology drugs. Its product portfolio includes a clinically approved cancer therapeutic and a late-stage oncology product targeting cancer treatment markets. The company sells its pharmaceutical products to healthcare providers and clinical channels.
When was Alchemia founded?
Alchemia was founded in 1995. It employs 11 to 50 people.
Where is Alchemia based?
Alchemia is headquartered in Eight Mile Plains, Australia, in the Oceania region.
Who are Alchemia's main competitors?
Broad incumbents on record are Telix Pharmaceuticals and Mayne Pharma. Direct peers are Clinuvel Pharmaceuticals, Bionomics, Sirtex Medical, Starpharma, Kazia Therapeutics, Imugene, Mesoblast and Pharmaxis.
Does Alchemia have an API?
No public API is recorded for Alchemia.
What industry is Alchemia in?
Alchemia's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAHAG, Oncology Biosimilars. Its NAICS code is 3254 and its SIC code is 2834.